cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.14555495
title: S9. FEG-TEM images of high pressure exfoliated graphene from Graphene production by cracking

description: In recent years, graphene has found its use in numerous industrial applications due to its unique properties. While its impermeable and conductive nature can replace currently used anticorrosive toxic pigments in coating systems, due to its large strength to weight ratio, graphene can be an important component as a next-generation additive for automotive, aerospace and construction applications. The current bottlenecks in using graphene and graphene oxide and other two-dimensional materials are the availability of cost-effective, high-quality materials and their effective incorporation (functionalization and dispersion) into the product matrices. On overcoming these factors, graphene may attract significant demands in terms of volume consumption. Graphene can be produced on industrial scales and through cost-effective top-down routes such as chemical, electrochemical and/or high-pressure mechanical exfoliation. Graphene, depending on end applications, can be chemically tuned and modified via functionalization so that easy incorporation into product matrices is possible. This paper discusses different production methods and their impact on the quality of graphene produced in terms of energy input. Graphene with an average thickness below five layers was produced by both methods with varied defects. However, a higher yield of graphene with a lower number of layers was produced via the high-pressure exfoliation route.This article is part of a discussion meeting issue ‘A cracking approach to inventing new tough materials: fracture stranger than friction’.
DOI: 10.6084/m9.figshare.14555486.v1
title: S8. FEG-TEM images of electrochemically exfolaited graphene from Graphene production by cracking

description: In recent years, graphene has found its use in numerous industrial applications due to its unique properties. While its impermeable and conductive nature can replace currently used anticorrosive toxic pigments in coating systems, due to its large strength to weight ratio, graphene can be an important component as a next-generation additive for automotive, aerospace and construction applications. The current bottlenecks in using graphene and graphene oxide and other two-dimensional materials are the availability of cost-effective, high-quality materials and their effective incorporation (functionalization and dispersion) into the product matrices. On overcoming these factors, graphene may attract significant demands in terms of volume consumption. Graphene can be produced on industrial scales and through cost-effective top-down routes such as chemical, electrochemical and/or high-pressure mechanical exfoliation. Graphene, depending on end applications, can be chemically tuned and modified via functionalization so that easy incorporation into product matrices is possible. This paper discusses different production methods and their impact on the quality of graphene produced in terms of energy input. Graphene with an average thickness below five layers was produced by both methods with varied defects. However, a higher yield of graphene with a lower number of layers was produced via the high-pressure exfoliation route.This article is part of a discussion meeting issue ‘A cracking approach to inventing new tough materials: fracture stranger than friction’.
DOI: 10.6084/m9.figshare.14555498
title: S5. X-ray diffractogram of high purity Ceylon vein graphite from Graphene production by cracking

description: In recent years, graphene has found its use in numerous industrial applications due to its unique properties. While its impermeable and conductive nature can replace currently used anticorrosive toxic pigments in coating systems, due to its large strength to weight ratio, graphene can be an important component as a next-generation additive for automotive, aerospace and construction applications. The current bottlenecks in using graphene and graphene oxide and other two-dimensional materials are the availability of cost-effective, high-quality materials and their effective incorporation (functionalization and dispersion) into the product matrices. On overcoming these factors, graphene may attract significant demands in terms of volume consumption. Graphene can be produced on industrial scales and through cost-effective top-down routes such as chemical, electrochemical and/or high-pressure mechanical exfoliation. Graphene, depending on end applications, can be chemically tuned and modified via functionalization so that easy incorporation into product matrices is possible. This paper discusses different production methods and their impact on the quality of graphene produced in terms of energy input. Graphene with an average thickness below five layers was produced by both methods with varied defects. However, a higher yield of graphene with a lower number of layers was produced via the high-pressure exfoliation route.This article is part of a discussion meeting issue ‘A cracking approach to inventing new tough materials: fracture stranger than friction’.
DOI: 10.6084/m9.figshare.14555498.v1
title: S5. X-ray diffractogram of high purity Ceylon vein graphite from Graphene production by cracking

description: In recent years, graphene has found its use in numerous industrial applications due to its unique properties. While its impermeable and conductive nature can replace currently used anticorrosive toxic pigments in coating systems, due to its large strength to weight ratio, graphene can be an important component as a next-generation additive for automotive, aerospace and construction applications. The current bottlenecks in using graphene and graphene oxide and other two-dimensional materials are the availability of cost-effective, high-quality materials and their effective incorporation (functionalization and dispersion) into the product matrices. On overcoming these factors, graphene may attract significant demands in terms of volume consumption. Graphene can be produced on industrial scales and through cost-effective top-down routes such as chemical, electrochemical and/or high-pressure mechanical exfoliation. Graphene, depending on end applications, can be chemically tuned and modified via functionalization so that easy incorporation into product matrices is possible. This paper discusses different production methods and their impact on the quality of graphene produced in terms of energy input. Graphene with an average thickness below five layers was produced by both methods with varied defects. However, a higher yield of graphene with a lower number of layers was produced via the high-pressure exfoliation route.This article is part of a discussion meeting issue ‘A cracking approach to inventing new tough materials: fracture stranger than friction’.
DOI: 10.6084/m9.figshare.14555492
title: S7. Scanning electron micrographs of exfoliated graphene from Graphene production by cracking

description: In recent years, graphene has found its use in numerous industrial applications due to its unique properties. While its impermeable and conductive nature can replace currently used anticorrosive toxic pigments in coating systems, due to its large strength to weight ratio, graphene can be an important component as a next-generation additive for automotive, aerospace and construction applications. The current bottlenecks in using graphene and graphene oxide and other two-dimensional materials are the availability of cost-effective, high-quality materials and their effective incorporation (functionalization and dispersion) into the product matrices. On overcoming these factors, graphene may attract significant demands in terms of volume consumption. Graphene can be produced on industrial scales and through cost-effective top-down routes such as chemical, electrochemical and/or high-pressure mechanical exfoliation. Graphene, depending on end applications, can be chemically tuned and modified via functionalization so that easy incorporation into product matrices is possible. This paper discusses different production methods and their impact on the quality of graphene produced in terms of energy input. Graphene with an average thickness below five layers was produced by both methods with varied defects. However, a higher yield of graphene with a lower number of layers was produced via the high-pressure exfoliation route.This article is part of a discussion meeting issue ‘A cracking approach to inventing new tough materials: fracture stranger than friction’.
DOI: 10.6084/m9.figshare.14161995.v1
title: Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity

description: Ruxolitinib, a selective Janus Kinase (JAK) 1/2 inhibitor, is a promising treatment for the steroid-refractory graft-vs-host disease (GvHD) after hematopoietic stem cell transplantation (HSCT). Most studies have been performed in the adult population showing efficacy against GvHD. In this retrospective study, we evaluated the outcomes of 19 children who received ruxolitinib for refractory acute or chronic GvHD (cGvHD) after HSCT from two Pediatric Hemato-Oncology Departments in Spain between March 2017 and December 2018. Patients received a median number of 4 (IQR 2) previous lines of treatment before starting ruxolitinib. The overall response rate in acute GvHD (aGvHD) and cGvHD was 87% and 91%, respectively. Complete response (CR) was observed in 37% of aGvHD and 8.3% of cGvHD. Remarkably, 43% and 40% of patients with steroid-refractory gastrointestinal aGvHD and lung cGvHD achieved CR. During ruxolitinib treatment, there were 36%, 31%, and 10% infections caused by viruses, bacteria, and fungi, respectively. Overall, four patients interrupted ruxolitinib due to infectious complications, hematological, and liver toxicity. The 2-year overall survival was 71.9% (CI 95% 58.6–85.2). Our experience supports the use of ruxolitinib as an effective treatment for steroid-refractory acute and cGvHD in children with a moderate toxicity profile.
DOI: 10.6084/m9.figshare.14161995
title: Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity

description: Ruxolitinib, a selective Janus Kinase (JAK) 1/2 inhibitor, is a promising treatment for the steroid-refractory graft-vs-host disease (GvHD) after hematopoietic stem cell transplantation (HSCT). Most studies have been performed in the adult population showing efficacy against GvHD. In this retrospective study, we evaluated the outcomes of 19 children who received ruxolitinib for refractory acute or chronic GvHD (cGvHD) after HSCT from two Pediatric Hemato-Oncology Departments in Spain between March 2017 and December 2018. Patients received a median number of 4 (IQR 2) previous lines of treatment before starting ruxolitinib. The overall response rate in acute GvHD (aGvHD) and cGvHD was 87% and 91%, respectively. Complete response (CR) was observed in 37% of aGvHD and 8.3% of cGvHD. Remarkably, 43% and 40% of patients with steroid-refractory gastrointestinal aGvHD and lung cGvHD achieved CR. During ruxolitinib treatment, there were 36%, 31%, and 10% infections caused by viruses, bacteria, and fungi, respectively. Overall, four patients interrupted ruxolitinib due to infectious complications, hematological, and liver toxicity. The 2-year overall survival was 71.9% (CI 95% 58.6–85.2). Our experience supports the use of ruxolitinib as an effective treatment for steroid-refractory acute and cGvHD in children with a moderate toxicity profile.
DOI: 10.6084/m9.figshare.12964607
title: Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review

description: Chronic graft-versus-host disease (GVHD) is a life-threating complication of allogeneic hematopoietic stem cell transplantation (HSCT) leading to high morbidity and quality of life issues. We conducted a systematic literature review on the patient reported symptom burden of chronic GVHD. English-language articles published between 2005 and November 2018 were searched using CENTRAL, EMBASE and MEDLINE. Studies that used the 2005 or 2015 National Institute of Health consensus criteria for the diagnosis and staging of chronic GVHD were included. Patient reported symptom burden was widely assessed in the literature (n = 38). The Lee Chronic GVHD Symptom Scale was the most frequently used instrument (n = 28), followed by the NIH Patient-reported Symptom scores (n = 11). Association of symptom burden with clinical outcome assessment endpoints (e.g. mortality) and with quality of life measures was investigated by fairly low number of studies with limited generalizability. By systematically investigating the influencing factors of symptom burden this review helps to better understand patients’ perceptions and may help improving the management and care of chronic GVHD. However, data on influencing factors was quite diverse, which indicates that specific questions identified as research gaps need to be incorporated in randomized clinical trials in a more systematic way.
DOI: 10.6084/m9.figshare.14137870
title: Clinical profile, outcome and challenges in the management of pediatric Burkitt lymphoma: a single center experience

description: This study was conducted with the aim to assess the clinico-pathological profile, treatment outcomes and the challenges faced in Low Middle Income Countries (LMIC) during management of pediatric Burkitt lymphoma cases on intensive chemotherapy protocol. This was a single center retrospective analysis of pediatric Burkitt lymphoma cases (age &lt;18 years) managed uniformly with Lymphomes Malins B (LMB) 96 chemotherapy protocol between January 2015 and September 2019. 40 cases were analyzed with a median age 11.5 years (range 4–18 years) and male: female ratio =4.7:1. Patients belonging to different LMB risk groups were: A-3 (7.5%), B-31 (77.5%), and C-06 (15%). 25 (62.5%) patients had abdominal disease at presentation. The survival analysis of different treatment risk groups showed statistically significant difference in mean Overall Survival (OS) between group A-100%, group B- 87%±6.1% and group C-44.4%±16.2%; (<i>p</i> value = .016). On multivariate analysis of prognostic factors affecting survival, CNS involvement (<i>p</i> value = .03) and median time from diagnosis to treatment initiation more than 30 days (<i>p</i> value = .04) were significantly associated with poor outcome. Incidence of culture positive febrile neutropenia episodes was 28.2% of which 69.2% infections were caused due to carbapenem resistant gram-negative organisms. In our study, although the outcomes in risk group A and B patients were comparable to LMB 96 treatment results, the outcome in risk group C was considerably poor primarily due to advanced disease at presentation and delayed diagnosis. The critical challenges that we faced in our cohort were delayed diagnosis, treatment cost affordability, poor nutritional status, and high infection related mortality.
DOI: 10.6084/m9.figshare.12964607.v1
title: Patient-reported symptom burden of chronic graft versus host disease: a systematic literature review

description: Chronic graft-versus-host disease (GVHD) is a life-threating complication of allogeneic hematopoietic stem cell transplantation (HSCT) leading to high morbidity and quality of life issues. We conducted a systematic literature review on the patient reported symptom burden of chronic GVHD. English-language articles published between 2005 and November 2018 were searched using CENTRAL, EMBASE and MEDLINE. Studies that used the 2005 or 2015 National Institute of Health consensus criteria for the diagnosis and staging of chronic GVHD were included. Patient reported symptom burden was widely assessed in the literature (n = 38). The Lee Chronic GVHD Symptom Scale was the most frequently used instrument (n = 28), followed by the NIH Patient-reported Symptom scores (n = 11). Association of symptom burden with clinical outcome assessment endpoints (e.g. mortality) and with quality of life measures was investigated by fairly low number of studies with limited generalizability. By systematically investigating the influencing factors of symptom burden this review helps to better understand patients’ perceptions and may help improving the management and care of chronic GVHD. However, data on influencing factors was quite diverse, which indicates that specific questions identified as research gaps need to be incorporated in randomized clinical trials in a more systematic way.
DOI: 10.6084/m9.figshare.14137870.v2
title: Clinical profile, outcome and challenges in the management of pediatric Burkitt lymphoma: a single center experience

description: This study was conducted with the aim to assess the clinico-pathological profile, treatment outcomes and the challenges faced in Low Middle Income Countries (LMIC) during management of pediatric Burkitt lymphoma cases on intensive chemotherapy protocol. This was a single center retrospective analysis of pediatric Burkitt lymphoma cases (age &lt;18 years) managed uniformly with Lymphomes Malins B (LMB) 96 chemotherapy protocol between January 2015 and September 2019. 40 cases were analyzed with a median age 11.5 years (range 4–18 years) and male: female ratio =4.7:1. Patients belonging to different LMB risk groups were: A-3 (7.5%), B-31 (77.5%), and C-06 (15%). 25 (62.5%) patients had abdominal disease at presentation. The survival analysis of different treatment risk groups showed statistically significant difference in mean Overall Survival (OS) between group A-100%, group B- 87%±6.1% and group C-44.4%±16.2%; (<i>p</i> value = .016). On multivariate analysis of prognostic factors affecting survival, CNS involvement (<i>p</i> value = .03) and median time from diagnosis to treatment initiation more than 30 days (<i>p</i> value = .04) were significantly associated with poor outcome. Incidence of culture positive febrile neutropenia episodes was 28.2% of which 69.2% infections were caused due to carbapenem resistant gram-negative organisms. In our study, although the outcomes in risk group A and B patients were comparable to LMB 96 treatment results, the outcome in risk group C was considerably poor primarily due to advanced disease at presentation and delayed diagnosis. The critical challenges that we faced in our cohort were delayed diagnosis, treatment cost affordability, poor nutritional status, and high infection related mortality.
DOI: 10.6084/m9.figshare.13099997
title: Taenia solium proteins: a beautiful kaleidoscope of pro and anti-inflammatory antigens

description: <b>Background:</b> Neurocysticercosis (NCC) is an acquired infection of central nervous system associated with epileptic seizures. The parasite ‘Taenia solium’ causes this disease and has a complex life cycle and molts into various stages that influence the host-parasite interaction. The disease has a long asymptomatic phase with viable cyst and degeneration of cyst and leaking cyst fluid has been associated with symptomatic phase. The parasite proteome holds the answers and clues to this complex clinical presentation and hence unraveling of proteome of parasite antigens is needed for better understanding of host-parasite interactions. <b>Objective:</b> To understand the proteome make-up of <i>T. solium</i> cyst vesicular fluid (VF) and excretory secretory proteins (ESPs). <b>Methodology:</b> The VF and ESPs for the study were prepared from cyst harvested from naturally infected swine. The samples were prepared for nano LC-MS by in-tube digestion of proteins. The spectra obtained were annotated and enrichment analysis was performed and <i>in silico</i> analysis was done. <b>Results:</b><i>T. solium</i> VF and ESPs have 206 and 247 proteins of varied make-up including pro-inflammatory and anti-inflammatory nature. <b>Conclusions:</b> Due to varied make-up of VF and ESPs it can generate complex humoral and cellular immune response.
DOI: 10.6084/m9.figshare.13099997.v1
title: Taenia solium proteins: a beautiful kaleidoscope of pro and anti-inflammatory antigens

description: <b>Background:</b> Neurocysticercosis (NCC) is an acquired infection of central nervous system associated with epileptic seizures. The parasite ‘Taenia solium’ causes this disease and has a complex life cycle and molts into various stages that influence the host-parasite interaction. The disease has a long asymptomatic phase with viable cyst and degeneration of cyst and leaking cyst fluid has been associated with symptomatic phase. The parasite proteome holds the answers and clues to this complex clinical presentation and hence unraveling of proteome of parasite antigens is needed for better understanding of host-parasite interactions. <b>Objective:</b> To understand the proteome make-up of <i>T. solium</i> cyst vesicular fluid (VF) and excretory secretory proteins (ESPs). <b>Methodology:</b> The VF and ESPs for the study were prepared from cyst harvested from naturally infected swine. The samples were prepared for nano LC-MS by in-tube digestion of proteins. The spectra obtained were annotated and enrichment analysis was performed and <i>in silico</i> analysis was done. <b>Results:</b><i>T. solium</i> VF and ESPs have 206 and 247 proteins of varied make-up including pro-inflammatory and anti-inflammatory nature. <b>Conclusions:</b> Due to varied make-up of VF and ESPs it can generate complex humoral and cellular immune response.
DOI: 10.6084/m9.figshare.12319724
title: Infant vaccine co-administration: review of 18 years of experience with GSK’s hexavalent vaccine co-administered with routine childhood vaccines

description: The benefits of vaccine co-administration include improved vaccine acceptance and uptake resulting in an increased coverage and protection against multiple childhood diseases, with minimal medical visits. The diphtheria-tetanus-acellular pertussis-hepatitis B-poliomyelitis-<i>Haemophilus influenzae</i> type b vaccine (DTaP-HBV-IPV/Hib) has been available for more than 19 years and is recommended for co-administration with several other infant vaccines. This is a comprehensive review (34 studies, 21,000 participants) describing the immunogenicity and safety of DTaP-HBV-IPV/Hib when co-administered with 12 different vaccines in infants including pneumococcal, meningococcal, rotavirus or measles-mumps-rubella-varicella. Interactions among co-administered vaccines are complex. Therefore, co-administration data are critical before a vaccination regimen can be recommended. Co-administration of DTaP-HBV-IPV/Hib with other routinely administered vaccines was associated with high percentages of children achieving seroprotection/vaccine response against DTaP-HBV-IPV/Hib antigens. In addition, co-administration was not associated with clinically significant interference in immune responses to co-administered vaccines and was well tolerated. Increased systemic reactions observed with some combinations (DTaP-HBV-IPV/Hib + pneumococcal conjugate or meningococcal serogroup B vaccines) were mitigated by prophylactic paracetamol administration. The data reported here, which represent the most frequently used co-administrations of DTaP-HBV-IPV/Hib worldwide, support the concomitant administration of DTaP-HBV-IPV/Hib with other routinely recommended infant vaccines.